tiprankstipranks
Trending News
More News >

Apellis downgraded to Neutral from Buy at BofA

BofA downgraded Apellis (APLS) to Neutral from Buy with a price target of $23, down from $41, following a “challenging” Q1. While lead drug Syfovre in geographic atrophy gained new patient share versus competition and sequential 4% underlying demand growth, it still missed estimates due in part to charitable foundation funding gaps, notes the analyst, who also points out that competitor Astellas has issued a 2025 sales guide for their product.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue